$75.79 0.00 (0.00%) Alnylam Pharmaceuticals Inc - NASDAQ

Aug. 23, 2016 | 04:00 PM
Last Trade: 75.79
Trade Time: Aug 23 04:00 PM Eastern Daylight Time
Change: +0.00 (0.00%)
Prev Close: 75.79
Open: 76.60
Bid: 50.00
Ask: 75.80
  1. No results found.
  1. Medicines Co. up on sale talk

    IBD | Jan. 20, 2016 | 18:40PM EST
  2. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  3. Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'

    Benzinga | Jan. 11, 2016 | 13:57PM EST
  4. Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B

    Benzinga | Dec. 7, 2015 | 10:30AM EST
  5. Breakaway Gaps By Stocks Can Be Scary But Profitable

    IBD | Dec. 3, 2015 | 17:58PM EST
  6. Leerink Highlights Biotechs Poised To Benefit From ASH Conference

    Benzinga | Nov. 30, 2015 | 13:13PM EST
  7. Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam ...

    GuruFocus | Nov. 17, 2015 | 10:50AM EST
  8. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga | Nov. 5, 2015 | 10:25AM EST
  9. Chardan Sees Promise Of ALN-PCSsc, Initiates The Medicines Co. With Buy

    Benzinga | Nov. 4, 2015 | 07:50AM EST
  10. Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

    Benzinga | Nov. 3, 2015 | 05:01AM EST
  11. Benzinga's Top Initiations

    Benzinga | Oct. 23, 2015 | 08:20AM EST
  12. Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders

    Benzinga | Oct. 8, 2015 | 16:01PM EST
  13. Julian Robertson Boosts His Stakes in JD.com, Netflix

    GuruFocus | Oct. 6, 2015 | 14:44PM EST
  14. Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

    Benzinga | Oct. 6, 2015 | 14:08PM EST
  15. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD | Sep. 24, 2015 | 10:51AM EST
Trading Center